| Literature DB >> 35116707 |
Libo Pan1, Xia Jia1, Xuewu Zhao1, Bei Zhang1, Shusheng Wang1, Tao Fan1, Min Zhou2, Yuan Yuan2, Guoqing Wang2, Longmei Xue1.
Abstract
BACKGROUND: The purpose of this study is to investigate the correlation between energy spectrum computed tomography (CT) imaging and the pathological characteristics and prognosis of cervical cancer.Entities:
Keywords: Energy spectrum CT imaging; cervical cancer; evaluation of curative effect; pathological features
Year: 2021 PMID: 35116707 PMCID: PMC8798028 DOI: 10.21037/tcr-21-1320
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Baseline information
| Item | Subtypes | n (%) |
|---|---|---|
| Age | >49 years | 13 (46.43) |
| ≤49 years | 15 (53.57) | |
| BMI | >23 | 11 (39.29) |
| ≤23 | 17 (60.71) | |
| Pathological type | Squamous cell carcinoma | 20 (71.43) |
| Adenocarcinoma | 5 (17.86) | |
| Squamous cell carcinoma with adenoid differentiation | 3 (10.71) | |
| Differentiated degree | Low differentiation | 2 (7.14) |
| Middle differentiation | 12 (42.86) | |
| High differentiation | 4 (14.29) | |
| Missing | 8 (28.57) | |
| Ki67 | High expression | 16 (57.14) |
| Low expression | 12 (42.86) |
BMI, body mass index; Ki67, cell proliferation antigen marker.
Figure 1Flow of participant involvement. CT, computed tomography.
Figure 2CT images. (A) Cervix (yellow circle); (B) uterine body (blue circle); (C) common iliac vein (purple circle). CT, computed tomography.
Relationship between CT value and pathological features of cervix
| Single energy (cervix) | Squamous cell carcinoma | Adenocarcinoma | Squamous cell carcinoma with adenoid differentiation | Low differentiation | Middle differentiation | High differentiation | High expression | Low expression |
|---|---|---|---|---|---|---|---|---|
| 40 keV | 178.94±36.86 | 212.08±37.48 | 199.37±31.73 | 228.36±27.39 | 182.15±24.97* | 188.66±22.38* | 227.13±44.69 | 187.39±48.02# |
| 50 keV | 130.44±22.76 | 152.61±25.12 | 143.51±53.82 | 161.42±19.35 | 131.92±18.97* | 137.68±18.09* | 161.41±28.91 | 136.64±30.56# |
| 60 keV | 100.59±14.49 | 116.02±17.60 | 109.10±36.78 | 120.32±14.48 | 101.03±14.24 | 106.32±19.47 | 103.58±19.46 | 105.38±20.14 |
| 70 keV | 82.03±9.79 | 93.27±13.06 | 87.78±26.31 | 94.28±11.62 | 81.79±9.69 | 86.82±14.19 | 83.79±13.88 | 85.97±13.95 |
| 80 keV | 70.15±7.44 | 78.72±10.22 | 74.08±19.69 | 77.82±9.85 | 69.50±7.16 | 74.33±10.97 | 71.12±10.60 | 73.54±10.39 |
| 90 keV | 62.29±6.46 | 69.08±8.43 | 65.07±15.47 | 66.92±8.77 | 61.34±5.84 | 66.08±8.94 | 62.73±8.74 | 65.32±8.42 |
| 100 keV | 56.83±6.22 | 62.39±7.22 | 58.76±12.64 | 59.33±7.89 | 55.68±5.28 | 60.33±7.65 | 56.91±7.67 | 59.59±7.41 |
| 110 keV | 56.83±6.17 | 57.66±6.45 | 54.32±10.74 | 54.00±7.42 | 51.72±5.10 | 56.28±6.83 | 52.80±7.14 | 55.56±6.95 |
| 120 keV | 52.98±6.32 | 54.44±5.93 | 51.31±9.53 | 50.32±7.03 | 48.99±5.11 | 53.53±6.30 | 50.02±6.87 | 52.83±6.79 |
| 130 keV | 50.37±6.50 | 51.82±5.58 | 48.83±8.63 | 47.40±6.78 | 46.76±5.17 | 51.28±5.94 | 47.72±6.72 | 50.57±6.76 |
| 140 keV | 48.21±6.69 | 49.78±5.31 | 46.91±8.03 | 45.07±6.54 | 45.02±5.27 | 49.53±5.71 | 45.94±6.68 | 48.84±6.81 |
*, P<0.05 compared with low differentiation; #, P<0.05 compared with high expression of Ki67. CT, computed tomography; Ki67, cell proliferation antigen marker.
Relationship between CT value and pathological characteristics of uterine body
| Single energy (uterine body) | Squamous cell carcinoma | Adenocarcinoma | Squamous cell carcinoma with adenoid differentiation | Low differentiation | Middle differentiation | High differentiation | High expression of Ki67 | Low expression |
|---|---|---|---|---|---|---|---|---|
| 40 keV | 219.53±39.94 | 271.70±35.98a | 257.67±38.93 | 209.25±65.75 | 227.19±38.59 | 218.89±66.12 | 229.75±63.48 | 235.88±39.40 |
| 50 keV | 156.76±22.54 | 192.20±23.48a | 175.74±26.11 | 151.23±43.78 | 160.97±24.34 | 157.23±45.03 | 162.45±41.03 | 168.30±26.69 |
| 60 keV | 118.16±22.04 | 143.19±10.61 | 130.33±30.47 | 115.29±30.26 | 120.28±15.75 | 119.29±32.20 | 121.03±27.37 | 126.70±19.06 |
| 70 keV | 94.16±15.71 | 112.88±9.59 | 100.13±21.52 | 93.11±21.89 | 94.97±10.66 | 95.71±24.38 | 95.31±19.04 | 100.88±14.63 |
| 80 keV | 78.82±11.86 | 93.39±8.93 | 80.82±15.76 | 78.79±16.54 | 78.80±7.65 | 80.64±19.41 | 78.86±13.82 | 84.33±11.98 |
| 90 keV | 68.64±9.53 | 80.59±8.62 | 68.10±12.03 | 68.55±13.08 | 68.06±6.03 | 70.67±16.22 | 67.96±10.56 | 73.40±10.44 |
| 100 keV | 61.58±8.10 | 71.59±8.39 | 59.24±9.50 | 62.93±10.61 | 60.62±5.24 | 63.74±14.05 | 60.37±8.48 | 65.79±9.44 |
| 110 keV | 56.61±7.27 | 65.26±8.19 | 52.98±7.79 | 58.21±8.79 | 55.39±4.88 | 58.81±12.65 | 55.07±7.23 | 60.41±8.82 |
| 120 keV | 53.19±6.80 | 60.94±8.10 | 48.66±6.59 | 55.19±7.57 | 51.76±4.84 | 55.46±11.65 | 51.37±6.49 | 56.76±8.45 |
| 130 keV | 50.45±6.49 | 54.47±8.09 | 45.23±5.68 | 52.59±6.64 | 48.88±4.85 | 52.82±10.91 | 48.42±6.02 | 53.83±8.18 |
| 140 keV | 48.29±6.30 | 54.79±7.99 | 42.53±5.07 | 50.62±5.95 | 46.61±4.93 | 50.66±10.35 | 46.13±5.71 | 51.48±8.01 |
a, P<0.05 compared with adenocarcinoma. CT, computed tomography; Ki67, cell proliferation antigen marker.
Relationship between CT values and pathological features of common iliac vein
| Single energy (common iliac vein) | Squamous cell carcinoma | Adenocarcinoma | Squamous cell carcinoma with adenoid differentiation | Low differentiation | Middle differentiation | High differentiation | High expression of Ki67 | Low expression of Ki67 |
|---|---|---|---|---|---|---|---|---|
| 40 keV | 303.74±57.76 | 327.79±48.83a | 330.68±51.79 | 398.05±43.70 | 292.62±47.15* | 300.63±49.41* | 304.88±55.37 | 320.36±56.94 |
| 50 keV | 211.53±37.79 | 226.75±17.80 | 228.67±45.97 | 273.09±27.41 | 203.88±30.18 | 209.59±32.35 | 211.87±35.66 | 222.61±37.41 |
| 60 keV | 154.85±25.69 | 164.64±11.68 | 165.95±30.18 | 196.29±13.61 | 149.31±20.04 | 153.64±21.98 | 154.74±23.67 | 162.48±25.59 |
| 70 keV | 119.64±18.32 | 126.02±7.88 | 127.03±20.47 | 148.38±11.17 | 115.47±14.13 | 118.86±15.68 | 119.24±16.37 | 125.13±18.30 |
| 80 keV | 97.05±13.82 | 101.28±5.50 | 102.08±14.42 | 117.78±9.82 | 93.70±10.71 | 96.59±11.78 | 96.48±11.86 | 101.18±13.89 |
| 90 keV | 82.20±11.09 | 85.00±4.20 | 85.60±10.66 | 97.69±8.72 | 79.43±8.88 | 81.89±9.54 | 81.49±9.13 | 85.43±11.23 |
| 100 keV | 71.84±9.33 | 73.75±3.32 | 74.15±8.28 | 73.71±7.84 | 69.46±7.90 | 71.72±8.06 | 71.08±7.39 | 74.46±9.43 |
| 110 keV | 64.51±8.25 | 65.59±2.83 | 66.07±6.81 | 73.65±7.71 | 62.40±7.45 | 64.54±7.09 | 63.66±6.35 | 66.65±8.41 |
| 120 keV | 59.44±7.57 | 60.07±2.58 | 60.39±6.01 | 66.71±7.11 | 57.53±7.25 | 59.45±6.58 | 57.54±5.76 | 61.20±7.70 |
| 130 keV | 55.45±7.18 | 55.63±2.43 | 56.02±5.60 | 61.26±6.99 | 53.72±7.21 | 55.47±6.24 | 54.53±5.46 | 57.02±7.28 |
| 140 keV | 52.31±6.90 | 52.24±2.46 | 52.55±5.39 | 57.08±6.82 | 50.66±7.22 | 52.42±6.01 | 51.36±5.27 | 53.72±7.01 |
*, P<0.05 compared with low differentiation; a, P<0.05 compared with adenocarcinoma. CT, computed tomography; Ki67, cell proliferation antigen marker.
Relationship between the energy spectrum curve slope and the pathological characteristics
| Energy spectrum curve slope (λ40–100) | Subtypes | Cervix | Uterine body | Common iliac vein |
|---|---|---|---|---|
| Pathological type | Squamous cell carcinoma | −1.14±0.31 | −1.45±0.41 | −2.05±0.49 |
| Adenocarcinoma | −1.41±0.28 | −1.81±0.93 | −2.29±0.23 | |
| Squamous cell carcinoma with adenoid differentiation | −1.23±0.53 | −1.79±0.54 | −2.31±0.59 | |
| P value | 0.2737 | 0.3100 | 0.4598 | |
| Differentiated degree | Low differentiation | −1.37±0.06 | −1.73±0.11 | −1.98±0.26 |
| Middle differentiation | −1.12±0.14 | −1.63±0.15 | −1.91±0.45 | |
| High differentiation | −1.04±0.04 | −1.67±0.13 | −1.93±0.20 | |
| P value | 0.0219 | 0.6064 | 0.9734 | |
| Ki67 | High expression | −1.12±0.35 | −1.52±0.33 | −1.98±0.38 |
| Low expression | −1.26±0.43 | −1.53±0.58 | −2.33±0.51 | |
| P value | 0.3508 | 0.9543 | 0.0052 |
Ki67, cell proliferation antigen marker.
Figure 3Energy spectrum curve of cervix, uterine body, and common iliac vein. The curves of each color represent the energy spectrum curves of each region of interest. No. 1-3 (yellow, red, pink) indicated cervical lesions. No. 4 (blue) indicated uterine body. No. 5 (dark blue) indicated common iliac vein. The curves represent the CT values of ROI under different KeV conditions. ROI, region of interest.
Changes in the energy spectrum curve slope before and after treatment
| Energy spectrum curve slope (λ40–100) | Curative effect | Before treatment | After treatment | P value |
|---|---|---|---|---|
| Cervix | Effective (CR + PR) | −1.18±0.31 | −0.85±0.29 | 0.0031 |
| Ineffective (SD + PD) | −1.11±0.46 | −0.98±0.33 | 0.4552 | |
| Uterine body | Effective (CR + PR) | −1.60±0.29 | −1.32±0.21 | 0.2785 |
| Ineffective (SD + PD) | −1.43±0.58 | −1.46±0.47 | 0.8953 | |
| Common iliac vein | Effective (CR + PR) | −2.10±0.38 | −1.79±0.31 | 0.0138 |
| Ineffective (SD + PD) | −2.16±0.54 | −2.13±0.32 | 0.8756 |
CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.
Figure 4ROC curve. (A) ROC curve of cervical energy spectrum curve slope to distinguish pathological grade; (B) ROC curve of energy spectrum curve slope of common iliac vein to distinguish the expression of Ki67. (C) ROC curve of cervical energy spectrum curve slope to distinguish the curative effect. (D) ROC curve of energy spectrum curve slope of common iliac vein to distinguish the curative effect. ROC, receiver operating characteristic; Ki67, cell proliferation antigen marker.